HK Stock Market Move | RIBOLIFE-B (06938) rises over 6% on plan to acquire remaining equity in Ribocure Pharmaceuticals AB.

RIBOLIFE-B (06938) rose over 6%, up 6.52% as of press time to HK$53.9, with a turnover of HK$2.5029 million. On the news front, RIBOLIFE-B announced that on October 16, 2026, the company entered into a share exchange agreement with minority shareholders, pursuant to which, subject to and in accordance with the terms and conditions of the share exchange agreement, the company has conditionally agreed to acquire, and the minority shareholders have severally and conditionally agreed to sell, the target shares (representing an aggregate of 49.71% of the total issued shares of the target company), such that the company will hold the entire equity interest in the target company. The target company, Ribocure Pharmaceuticals AB, is a clinical-stage biotechnology company organized under Swedish law in February 2022. As the company's international R&D center, the target company is primarily engaged in global clinical development and translational research of oligonucleotide therapeutics, with a particular focus on siRNA drugs targeting cardiovascular, metabolic, hepatic, renal and neurodegenerative diseases. The target company currently has five drug discovery and preclinical-stage projects, of which two have advanced to near clinical filing stage and two are major out-licensing collaboration projects.